3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
4
Lung Neoplasms
4
Advanced Solid Tumors
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Hereditary Sensory and Autonomic Neuropathies
1
Healthy Participants
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
sotorasib
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled